Profit

Lupin launches generic GERD drug in the US market

 Share
EMAIL
PRINT
COMMENTS
New Delhi: 

Drug major Lupin today said it has launched a generic version of Japan-headquartered Eisai Inc's Aciphex delayed-release tablets, used to treat gastroesophageal reflux disease, in the US market.

The company's US-based subsidiary Lupin Pharmaceuticals Inc has launched its generic Rabeprazole Sodium delayed-release tablets, 20 mg in the American market after having received approval to market it from the US Food and Drug Administration, according to a statement by Lupin.

Lupin's product is generic equivalent of Eisai Inc's Aciphex delayed-release tablets, 20mg, and is indicated for the treatment of gastroesophageal reflux disease (GERD), it added.

According to IMS MAT Jun 2013 sales data, Aciphex delayed-release tablets, 20mg, had annual US sales of around USD 864.3 million.

Shares of Lupin were trading at Rs 886.30 a piece on the BSE in late afternoon trade, up 0.30 per cent from its previous close.



Get Breaking news, live coverage, and Latest News from India and around the world on NDTV.com. Catch all the Live TV action on NDTV 24x7 and NDTV India. Like us on Facebook or follow us on Twitter and Instagram for latest news and live news updates.

NDTV Beeps - your daily newsletter

................................ Advertisement ................................

................................ Advertisement ................................

................................ Advertisement ................................

Top